Drug Information

Drug General Information
Drug ID
D05ODU
Former ID
DIB010524
Drug Name
Belerofon
Synonyms
IFNa; IFN-beta
Indication HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10:B17.1, B18.2] Phase 1 [551542]
Company
Nautilus Biotech
Target and Pathway
Target(s) IFN-alphaR Target Info Modulator [550137]
KEGG Pathway Cytokine-cytokine receptor interaction
PI3K-Akt signaling pathway
Osteoclast differentiation
Toll-like receptor signaling pathway
Jak-STAT signaling pathway
Natural killer cell mediated cytotoxicity
Hepatitis C
Hepatitis B
Measles
Influenza A
Herpes simplex infection
NetPath Pathway TCR Signaling Pathway
Leptin Signaling Pathway
PANTHER Pathway Inflammation mediated by chemokine and cytokine signaling pathway
Pathway Interaction Database Downstream signaling in na&#xef
Reactome Interferon alpha/beta signaling
Regulation of IFNA signaling
WikiPathways Toll-like receptor signaling pathway
Interferon type I signaling pathways
Interferon alpha/beta signaling
Regulation of toll-like receptor signaling pathway
Osteoclast Signaling
References
Ref 551542Nautilus Biotech Receives FDA Approval for Phase 1 Clinical Trial in the USA for Oral Belerofon(R), its Long-Lasting, Interferon-Alpha Drug. Nautilus Biotech. MAY 14, 2007.
Ref 550137WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same.